Boston University

A & D Bioscience, Inc.

University of Colorado

A and D Assay, Incorporated

Rahul Ray

Michael F Holick

Narasimha Swamy

Jim Lambert

Ann Thor

Hamid Gari

Scott Lucia

Scott C Mohr

A targeted approach toward the treatment of TN breast cancer by using AMPI-109 is disclosed. AMPI-109 is a compound with remarkable 'cancer-specific' characteristics. In particular, AMPI-109 demonstrates a striking targeted capability to inhibit the proliferation of TN breast cancer cells and to induce apoptosis in TN breast cancer cells. The growth inhibitory effect of AMPI-109 is independent of VDR. AMPI-109 can also be coupled with other oncolytic agents in treating a patient with TN breast cancer.

Method for treating triple-negative breast cancer using AMPI-109

An estrogen/antiestrogen-porphyrin conjugate, their composition and methods for their use are claimed. The active compounds of the invention are conjugates consisting of an estrogen or anti estrogen portion, tether or linker portion and a porphyrin portion. The method of invention exploits an active process that involves strong and specific interactions between nuclear receptor and its cognate ligand.

Selective nuclear receptor-targeted systems for delivery of cytotoxins to cancer cells for targeted photodynamic therapy

Biotin, fluorescent and chemiluminescent labeled vitamin D compounds are disclosed as well as their use in assays for the presence of vitamin D, its metabolites and vitamin D analogs in biological fluids.

Labeled vitamin D compounds and the use thereof

Kit comprising biotin, fluorescent and chemiluminescent labeled vitamin D compounds are disclosed. The disclosed kit may be used in assays for the presence of vitamin D, its metabolites and vitamin D analogs in biological fluids.

Kits comprising labeled vitamin D compounds

Growing community of inventors

Wayland, MA, United States of America

Rahul Ray